Results 231 to 240 of about 636,444 (331)

Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data

Clinical Pharmacology &Therapeutics, EarlyView.
This study compared the number and cumulative dose of antibiotic dispensings among new users of sodium–glucose cotransporter‐2 (SGLT2) inhibitors and dipeptidyl peptidase‐4 (DPP4) inhibitors following hospital discharge in individuals with type 2 diabetes.
Maria J. Alfonso Arvez, George S. Q. Tan, Sam Wade, Zanfina Ademi, Jenni Ilomäki, J. Simon Bell   +5 more
wiley   +1 more source

EFFECTS OF ADRENALINE AND NORADRENALINE ON ATRIAL FIBRILLATION PRODUCED BY ACETYLCHOLINE: WITH OBSERVATIONS ON THE MECHANISM OF FIBRILLATION [PDF]

, 1964
P L Sharma
openalex   +1 more source

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT‐ACS Emulation Using National Health Insurance Claims Data

Clinical Pharmacology &Therapeutics, EarlyView.
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang, Yee‐Jen Wu, Fang‐Ju Lin, Chien‐Chih Wu, Hsin‐Yi Huang, Chi‐Chuan Wang, Xiaojuan Li   +6 more
wiley   +1 more source

ALCAPA Diagnosed in an Elderly Patient. [PDF]

JACC Case Rep
Pointer TC, Keaney JF, Reinhardt SW, Pastor T.   +3 more
europepmc   +1 more source

Lidocaine in Cardiac Resuscitation from Ventricular Fibrillation

, 1956
NORMAN L. CARDEN, John E. Steinhaus
openalex   +1 more source

Clinical Trials With Pragmatic Elements: A Review of Use Cases and Real‐World Data Utilization

Clinical Pharmacology &Therapeutics, EarlyView.
Clinical trials with pragmatic elements can capture diverse patient populations, enable efficient follow‐up, and reflect routine clinical practices; yet there is limited understanding of their design features, characteristics, and use of real‐world data (RWD). Based on a targeted search of PubMed/EMBASE (Jan‐2016 to Jul‐2024), a review was conducted to
Le Su, Lei Chen, Seema Betigeri, Nancy Dreyer, Helga Gardarsdottir, Rachele Hendricks‐Sturrup, Mehmet Burcu   +6 more
wiley   +1 more source

Utility of biological aging acceleration in capturing transitions of atrial fibrillation and dementia: a population-based study. [PDF]

NPJ Aging
Liu Y, Li C.
europepmc   +1 more source

Effect of Reserpine on Atrial and Ventricular Rates in Atrial Fibrillation in Man [PDF]

, 1965
Walter Modell, Allen E. Hussar
openalex   +1 more source

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

Clinical Pharmacology &Therapeutics, EarlyView.
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou, Emily Bozenhardt, Gregory E. Alexander, Matthew L. Zierhut, Samira Merali, Antoinette Ajavon‐Hartmann, Peter Zannikos, Hyunmoon Back, EunYoung Suh, Navin Goyal, Mahesh N. Samtani, Alexei N. Plotnikov, Chandni Valiathan   +12 more
wiley   +1 more source

Short-term benefit of early rhythm control for atrial fibrillation: the EAST-AFNET 4 trial. [PDF]

Eur Heart J
Obergassel J, Suling A, Borof K, Camm AJ, Crijns HJGM, Eckardt L, Fabritz L, Goette A, Jensen M, Lemoine MD, Magnussen C, Metzner A, Rillig A, Schotten U, Schnabel R, Thomalla G, Vardas P, Wakili R, Willems S, Zapf A, Kirchhof P, Schrage B.   +21 more
europepmc   +1 more source